Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China To Issue Plan For Invigorating Bioindustry

This article was originally published in PharmAsia News

Executive Summary

China's National Development and Reform Commission is pushing for the development of the bioindustry, which so far has been little impacted by the global financial crunch. The sector grew 25.5 percent in 2008, hitting over RMB 860 billion in production value. NDRC has submitted policies for invigorating the industry to the State Council for approval. Three key national science and technology projects will commence this year - AIDS, prevention and treatment of viral hepatitis, as well as transgenic research. In addition, NDRC will work closely with the nine key bioindustry projects under China's Eleventh Five-Year Plan (2006-2011) to focus on the commercialization of green agricultural products, microorganism production, as well as modern TCM. (Click here for more - Chinese Language)

You may also be interested in...



Coronavirus Notebook: US FDA's Paper Push, Industry Exes/US Officials Emphasize Their Collaboration

Dispatches from a world turned upside down include FDA expressing confidence in Chinese manufacturers – to make their GDUFA payments; projections of drug shortages for ventilator patients; and the launch of new hydroxychloroquine studies.

Good News For Immunomedics' Triple Negative Breast Cancer Trial

A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.

Takeda, CSL, Other Blood Plasma Firms Team On Hyperimmune COVID-19 Therapy

Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.

UsernamePublicRestriction

Register

SC071199

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel